TORONTO, May 27, 2023 /PRNewswire/ -- Cora Therapeutics, a
dynamic life sciences startup based in Toronto, proudly unveils the results of a
clinical trial at the Canadian Association of Interventional
Radiologists (CAIR) annual meeting in Quebec City. Dr. Kieran Murphy MD, FRCPC, FSIR, Founder,
Inventor, and CMO of Cora Therapeutics, announced the efficacy of a
proprietary antioxidant complex in safeguarding DNA from radiation
exposure during life-saving aortic aneurysm stenting procedures
guided by X-ray technology.
During these high-intensity image-guided procedures, physicians
were administered the antioxidant complex as two capsules, one hour
prior to exposure. The results clearly showed the treated group
experiencing a significant 78% reduction in DNA breaks detected by
P53 tests in their cell nucleus, surpassing expectations compared
to the placebo group.
Dr. Murphy's team has successfully demonstrated the protection
of mitochondrial DNA from radiation in these subjects, marking a
significant milestone in medical literature. The group given the
antioxidant formulation exhibited a 54% decrease in mitochondrial
DNA damage based on STAT 3 testing when compared to the placebo
group. Considering that mitochondrial DNA is inherited maternally
and is 13 times more vulnerable to radiation than nuclear DNA, this
achievement holds tremendous promise.
The rigorous DNA analysis was conducted by two independent teams
of scientists, one at Princess Margaret Hospital, University Health
Network, Toronto, and the other at
McMaster University, Hamilton, Ontario, Canada. These institutions
are recognized as leading academic health sciences centres in
Canada. The research findings,
representing a breakthrough in the field, will now undergo the
peer-reviewed publication process. This antioxidant formulation has
the potential to mitigate DNA breaks in patients undergoing CT
scans, X-rays, mammography, angiography, dental X-rays, and could
become an integral part of the daily routine for the 2 million
healthcare workers worldwide who perform cardiac and angiographic
interventions under X-ray guidance or work in radiology and
cardiology departments.
Dr. Murphy's previous prospective, randomized human study
showcased an impressive over 90% reduction in DNA breaks among
patients undergoing Nuclear Medicine bone scans. This pioneering
research was published in the Journal of Vascular Interventional
Radiology in 2016.
Radiation, classified as an oxidative stressor, leads to the
accumulation of harmful free radicals in the body, much like air
pollution, UV light, smoking, processed diets, and frequent flying.
Unprotected, these deleterious free radicals infiltrate DNA,
elevating the risk of DNA damage and gene mutation. However, the
Halo antioxidant complex, which can be taken daily or one
hour before radiation exposure, has demonstrated significant
efficacy in reducing DNA breaks, as indicated by the collected
data.
Halo is an antioxidant formulation that consists of
carefully selected natural ingredients that comply with NHPD
guidelines, ensuring maximum safety and optimal efficacy while
upholding the highest standards for nutraceutical products. The
patented blend of ingredients effectively neutralizes free
radicals, preventing them from damaging the body's cells. Cora
Therapeutics has employed pharmaceutical-level scientific rigor to
develop this innovative nutraceutical.
Halo has received clearance from Health Canada and
the FDA. It is protected by four issued patents globally and has
been the subject of nine peer-reviewed publications, solidifying
its scientific validity and potential.
About Cora Therapeutics:
Cora Therapeutics is at the forefront of data-driven health
solutions as an innovative Toronto-based company. Under the leadership of
Dr. Kieran Murphy, a renowned
interventional neuroradiologist, the expert team behind Halo
is committed to minimizing the collateral damage caused by
radiation exposure. With over 80 patents and more than 180
peer-reviewed publications to his name, Dr. Murphy is a global
leader in the field of interventional neuroradiology, practicing at
the University Health Network in Toronto.
The team is complemented by the esteemed scientific advisor, Dr.
Mark Tarnopolsky, MD Ph.D. FRCPC,
who is a frontrunner in evaluating and developing nutraceutical
treatments for disorders associated with oxidative stress. These
dedicated clinician-scientists are supported by a robust team of
health and wellness innovators experienced in bringing
revolutionary products to market.
To learn more about Cora Therapeutics, please visit
www.coratherapeutics.com and for detailed information on
Halo, visit www.haloantioxidant.com
CONTACT: Dr. Kieran
Murphy, kieran.murphy@uhn.ca
Logo -
https://mma.prnewswire.com/media/2087072/Cora_Therapeutics_Dr__Kieran_Murphy_Presents_Results_of_Clinical.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/dr-kieran-murphy-presents-results-of-clinical-trial-demonstrating-positive-effect-protecting-dna-from-radiation-exposure-301836237.html